ArticleCureus2025
Magnitude and Predictors of Subclinical Hypothyroidism in Individuals With Impaired Glucose Tolerance.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe screening for thyroid function abnormalities in asymptomatic individuals remains a topic of debate. The impact of subclinical hypothyroidism (SCH) on glucose metabolism has been less extensively researched. Our study aimed to assess the feasibility of thyroid-stimulating hormone (TSH)-based screening and evaluate the prevalence of SCH among individuals with impaired glucose tolerance (IGT) in a community-based setting. Methodology: We performed a longitudinal study in individuals with IGT by measuring clinical parameters and TSH at baseline and follow-up measurements at 6 and 12 months.
resultsWe included 148 participants with IGT. The baseline mean HbA1c of the participants was 6.0% ± 0.2%, and the TSH level was 3.2 ± 2.1 µIU/mL. In the study, we found that 18 (12.2%) individuals with IGT had baseline TSH values in the SCH range (TSH 5-10 µIU/mL). Individuals with IGT who also had a TSH abnormality had significantly lower HbA1c levels as compared to those who were euthyroid (5.9% ± 0.2% vs. 6.1% ± 0.2%,
conclusionsThe study highlights that SCH is a transient condition among individuals with IGT. The majority of these individuals reverted to normal thyroid function after one year without requiring thyroid hormone therapy, underscoring the unstable nature of SCH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.